

# Câncer de Endométrio

## **Carboplatina + Paclitaxel**

Carboplatina: AUC 5-7 IV D1

Paclitaxel: 175mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (1)

## **Adriamicina + Ciclofosfamida**

Doxorrubicina: 60mg/m<sup>2</sup> IV D1

Ciclofosfamida: 500mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (2)

## **Adriamicina + Cisplatina**

Doxorrubicina: 50mg/m<sup>2</sup> IV D1

Cisplatina: 50mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref.(3)

## **Adriamicina + Paclitaxel**

Doxorrubicina: 50mg/m<sup>2</sup> IV D1

Paclitaxel: 150mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (4)

## **Cisplatina + Doxorrubicina + Paclitaxel**

Cisplatina: 50mg/m<sup>2</sup> IV D1

Doxorrubicina: 45mg/m<sup>2</sup> IV D1

Paclitaxel: 160mg/m<sup>2</sup> IV D2

Filgrastima: 5mcg/kg SC D3-D12

a cada 21 dias

Ref. (5)

### **CAP**

Ciclofosfamida: 500mg/m <sup>2</sup>	IV	D1
Doxorrubicina: 50mg/m <sup>2</sup>	IV	D1
Cisplatina: 500mg/m <sup>2</sup>	IV	D1 a cada 21 dias

Ref. (6)

### **Carboplatina + Doxorrubicina Lipossomal**

Carboplatina: AUC 5	IV	D1
Doxo lipossomal: 40mg/m <sup>2</sup>	IV	D1 a cada 28 dias

Ref. (7)

### **Doxorrubicina**

Doxorrubicina: 60mg/m <sup>2</sup>	IV	D1 a cada 21 dias
------------------------------------	----	-------------------

Ref. (8)

### **Paclitaxel**

Paclitaxel: 200mg/m <sup>2</sup>	IV	D1 a cada 21 dias
Se RXT prévia: 175mg/m <sup>2</sup>	IV	D1 a cada 21 dias

Ref. (9)

### **Topotecano**

Topotecano: 1mg/m <sup>2</sup> /dia	IV	D1-D5 a cada 21 dias
Se RXT prévia 0,8mg/m <sup>2</sup> /dia	IV	D1-D5 a cada 21 dias

Ref. (10)

### **Acetato de Megestrol**

Acetato de megestrol: 160mg	VO	Contínuo
-----------------------------	----	----------

Ref.(11)

### **Tamoxifeno**

Tamoxifeno: 20mg	VO	Contínuo
------------------	----	----------

Ref.(12)

### **Anastrozol**

Anastrozol: 1 mg/dia VO contínuo

Ref. (13)

### **Letrozol**

Letrozol: 2,5 mg VO dia contínuo

Ref. (14)

### **Ifosfamida**

Ifosfamida: 1200mg/m<sup>2</sup> IV

Mesna: 300 mg/m<sup>2</sup> IV D1 a D5 a cada 28 dias  
concomitante, 4 e 8hs após ifosfamida

Ref. (15)

### **Doxorrubicina lipossomal**

Doxorrubicina lipossomal: 40mg/m<sup>2</sup> IV D1 28 dias

Ref. (16)

1. Hoskins, P.J., *et al.* Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. *J Clin Oncol*, 2001. 19(20): p. 4048-53.
2. Thigpen, J.T., *et al.* A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol*, 1994. 12(7): p. 1408-14.
3. Deppe, G., *et al.* Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. *Eur J Gynaecol Oncol*, 1994. 15(4): p. 263-6.
4. Fleming G. F., Filiaci V. L., Bentley R. C, *et. al.* Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a

Gynecologic Oncology Group study. *Ann Oncol*. 2004; 15(8): 1173-1178.

5. Fleming, G.F., *et al.* Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. *J Clin Oncol*, 2004. 22(11): p. 2159-66.
6. Burke, T.W., *et al.* Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. *Gynecol Oncol*, 1994. 55(1): p. 47-50.
7. Pignata, S., *et al.* A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. *Br J Cancer*, 2007. 96(11): p. 1639-43.
8. Muss, H.B., Chemotherapy of metastatic endometrial cancer. *Semin Oncol*, 1994. 21(1): p. 107-13.
9. Ball, H.G., Do we know the best therapy for early endometrial cancer? *Gynecol Oncol*, 1996. 60(2): p. 173-5.
10. Wadler, S., *et al.* Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. *J Clin Oncol*, 2003. 21(11): p. 2110-4.
11. Thigpen, J.T., *et al.* Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. *J Clin Oncol*, 1999. 17(6): p. 1736-44.
12. Thigpen, T., *et al.* Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*, 2001. 19(2): p. 364-7.
13. Rose PG, Brunetto, VL, *et al.* A Phase II trial of Anastrozolein advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group Study. *Gynecologic Oncology*, 2000; 78, 212-216.

- 14.** Ma B B.Y, Oza A, *et al.* The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group, Intern J Gynecol Cancer 2004. 14(4):650 - 658.
- 15.** Sutton GP, *et al.* A Phase II Gynecologic Oncology Group Trial of Ifosfamide and Mesna in Advanced or Recurrent Adenocarcinoma of the Endometrium. Gynecol Oncol. Gynecol Oncol 1996;63:25-7.
- 16.** Homesley, HD, *et. al.* Phase II trial of liposomal doxorubicin at 40 mg/m<sup>2</sup> every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study Gynecol Oncol 2005; 98:294-8.